DARRIN UECKER - 01 Nov 2023 Form 4 Insider Report for Pulse Biosciences, Inc. (PLSE)

Role
Chief Technology Officer, Director
Signature
/s/ Kenneth B. Stratton, as Attorney-in-Fact
Issuer symbol
PLSE
Transactions as of
01 Nov 2023
Transactions value $
$0
Form type
4
Filing time
03 Nov 2023, 17:36:40 UTC
Previous filing
14 Jul 2023
Next filing
16 Jun 2025
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction PLSE Stock Option (right to buy) Award $0 +330,000 $0.000000 330,000 01 Nov 2023 Common Stock 330,000 $4.38 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 100% vesting upon the earlier of (i) the six (6) year anniversary of the grant date, and (ii) the 1-year anniversary of a Company change of control.